Curis Received Notice of Delisting

Curis (CRIS) received a Nasdaq delisting notice for failing to maintain a minimum $1.00 bid price. The company plans to request a hearing to appeal, but success is not guaranteed. Curis is ineligible for a standard compliance period due to a recent reverse stock split and a one-year Panel Monitor.

Original reporting
Published Nov 6, 2026, 9:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Curis Received Notice of Delisting — source image
Decision brief

The 30-second read

$CRISBearishMed
01

Why it matters

The delisting determination is a material corporate action that can erode investor confidence and liquidity, likely driving the share price lower.

02

Market read

A primary 8‑K filing announcing a delisting notice is a high‑impact corporate event for a listed micro‑cap, warranting immediate trader attention.

03

What to watch

Potential for a reverse split or capital raise that could restore price above $1, mitigating delisting risk.

Relevance 6/10Novelty 8/10Timing: immediate

Background

Curis Inc. (CRIS) is a clinical‑stage biotech listed on Nasdaq. The company recently completed a 1‑for‑20 reverse split and is under a one‑year Panel Monitor.

Company-level read

Ticker impact

$CRISBearishHigh confidence
Context

Curis received a Nasdaq delisting determination after its share price stayed below $1 for 30 days, triggering a potential removal from the exchange.

Expected impact

downward pressure as investors price in the risk of delisting and possible loss of liquidity

Evidence & confidence

A primary 8‑K filing announcing a delisting determination is material and new; market participants typically sell on such news.

Market effects

May prompt scrutiny of other low‑price Nasdaq stocks and could tighten listing compliance monitoring.

Limited to U.S. small‑cap and biotech investors; no broader regional effect.

Minimal global impact; primarily a micro‑cap event.

Counterpoint

If Curis successfully appeals the delisting and regains compliance, the stock could rebound on short‑covering.

Key entities

  • Curis Inc.

    Biotech firm facing Nasdaq delisting determination.

Related articles

$CRISHigh

Curis Provides Third Quarter 2026 Business Update

CURIS INC (CRIS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2026 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of

$CRISMed

Curis (CRIS) Q3 2026 Earnings Call Transcript

Curis (CRIS) reported Q3 2026 net loss of $8.1M, narrower than 2025. The company is advancing clinical trials for emavusertib in NHL and CLL, with initial data expected by year-end. They aim for accelerated approval submissions in 2027. Cash reserves are $5M, expected to fund operations into 2027.

$CRISMedAI 8/10

Curis Provides Third Quarter 2026 Business Update

Curis, Inc. (CRIS) reported Q3 2026 financial results, showing a net loss of $8.1M, and provided a business update. The company is conducting studies on emavusertib for CLL and PCNSL, with initial data expected in December 2026. Curis completed a public offering and a private placement, extending its cash runway into 2027. Management will host a conference call to discuss the update.

$CRISMedAI 8/10

Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

$CRISMed

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

$CRISMedAI 8/10

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.